CVE-2024-13161
Published: March 10, 2025
Official Description
Ivanti Endpoint Manager (EPM) contains an absolute path traversal vulnerability that allows a remote unauthenticated attacker to leak sensitive information.
CISA KEV Advisory
Ivanti Endpoint Manager (EPM) Absolute Path Traversal Vulnerability
Ivanti Endpoint Manager (EPM) contains an absolute path traversal vulnerability that allows a remote unauthenticated attacker to leak sensitive information.
Apply mitigations per vendor instructions, follow applicable BOD 22-01 guidance for cloud services, or discontinue use of the product if mitigations are unavailable.
Risk Analysis
This absolute path traversal vulnerability in Ivanti Endpoint Manager (EPM) allows a remote unauthenticated attacker to leak sensitive information. It is a high-severity flaw with a very high EPSS score of 0.91641, indicating a high likelihood of exploitation, and is confirmed to be actively exploited.
Active exploitation of this vulnerability has been observed in the wild. It is remotely exploitable and does not require authentication.
Administrators should apply the latest security updates for Ivanti Endpoint Manager (EPM) to address this path traversal vulnerability.
Technical Analysis
CVE-2024-13161 requires local access, meaning attackers must already have a foothold on the target system.
Exploitation requires some privileges, which limits the exposure to scenarios where an attacker has already gained initial access.
CISA has added CVE-2024-13161 to the Known Exploited Vulnerabilities (KEV) catalog, confirming active exploitation in the wild. U.S. federal agencies are required to patch this within the mandated timeframe, and all organizations should treat remediation as urgent.
Exploit & PoC Resources
All References (2)
Quick Facts
Recommended Actions
- →Apply vendor patches immediately
- →Monitor CVE-2024-13161 in threat intel feeds
- →Review IDS/IPS signatures for exploitation attempts
- !CISA KEV: Federal agencies must patch per BOD 22-01 timeline
- !Active exploitation confirmed — treat as P1